FDA Tablet Scoring Guidance Holds Brands, Generics To Single Standard
This article was originally published in The Tan Sheet
Executive Summary
Generic and private label industry concerns that scoring conventions could create barriers to market entry did not win out in the agency’s final tablet scoring guidance. FDA advises firms to contact the agency when questions arise about a product’s scoring being patent-protected.